

产品名称: **LJI308**

产品别名: **LJI308**

生物活性:					
Description	LJI308 is a new and potent pan-RSK inhibitor, with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively. IC50 value: 6/4/13 nM Target: RSK1/2/3 in vitro: LJI308 efficiently inhibits RSK activity. LJI308 inhibits S6K1 with an IC50 of 0.8 μ M, representing a 200-fold lower inhibition than that of RSK2. LJI308 inhibits MEK4 less than 50% at 10 μ M and HIP kinase 1 less than 50% at 1 μ M. [1] LJI308 inhibits the growth and survival of TNBC. LJI308 also suppresses the growth of HTRY-LT cells in 3-dimensional soft agar cultures. LJI308 is one of the first potent and effective targeted therapies for TNBC that, unlike currently utilized drugs, exhibits efficacy in eliminating the CSC population. [2]				
Solvent&Solubility	In Vitro: DMSO : 25 mg/mL (67.86 mM; Need ultrasonic)				
		Solvent Mass Concentration	1 mg	5 mg	10 mg
	Preparing	1 mM	2.7146 mL	13.5729 mL	27.1459 mL
	Stock Solutions	5 mM	0.5429 mL	2.7146 mL	5.4292 mL
		10 mM	0.2715 mL	1.3573 mL	2.7146 mL
	*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。 -80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。				
References	[1]. Aronchik I, et al. Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers. <i>Mol Cancer Res.</i> 2014 May;12(5):803-12. [2]. Davies AH, et al. Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells. <i>Oncotarget.</i> 2015 Aug 21;6(24):20570-7. [3]. Jain R, et al. Discovery of Potent and Selective RSK Inhibitors as Biological Probes. <i>J Med Chem.</i> 2015 Sep 10;58(17):6766-83.				

源叶生物